Shanghai Shen Lian Biomedical Corporation (688098.SH): UBI plans to reduce its shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH) announced that United Biomedical, Inc. (UBI) in the United States is in need of funds to advance its clinical trials for Alzheimer's disease synthetic peptide vaccines and other innovative drugs, commercialization efforts, and accelerate the construction of a peptide-related production manufacturing base in partnership with Chinese partners. UBI plans to reduce its holdings of the company's shares by 410,640 shares through centralized competitive trading on the Shanghai Stock Exchange trading system within 3 months after the disclosure date of the announcement, not exceeding 1% of the company's total shares; and by 821,290 shares through block trading, not exceeding 2% of the company's total shares.